Archives
-
Murine RNase Inhibitor: Scope and Evidence
2026-10-14
APExBIO describes Murine RNase Inhibitor (K1046) as a recombinant 50 kDa mouse protein that selectively binds pancreatic-type RNases. Its documented scope is narrower than broad RNA protection: the product description supports a mechanistic rationale for inhibiting RNase A, B, and C, while providing no identity-matched research study, comparative effect size, or independent validation of workflow performance.
-
EPZ5676 and DOT1L in Renal Fibrosis
2026-10-14
A 2019 FASEB Journal study links increased DOT1L activity and H3K79 dimethylation to experimental renal fibrosis, while reporting that pharmacologic or genetic DOT1L inhibition attenuated fibrotic responses. The findings are mechanistically suggestive but remain preclinical and model-limited.
-
What the NSP15 Screening Study Actually Shows
2026-10-13
A 2021 computational study identified thymopentin and oleuropein as leading predicted binders of SARS-CoV-2 NSP15. Its results support hypothesis generation, not evidence that either compound inhibits the virus or improves COVID-19 outcomes. Tetrandrine was not reported as a leading hit in this study.
-
Ribociclib, pH, and the Limits of In Vitro Evidence
2026-10-13
A 2024 Journal of Chromatographic Science study examined whether physiologically relevant pH shifts could alter ribociclib succinate solubility in a way that might raise concerns about acid-reducing agents. Its results support limited pH sensitivity within the tested in vitro model, but they do not independently establish unchanged absorption or clinical safety during coadministration.
-
A Biomimetic mRNA Vaccine Targets Tumor Neutrophils
2026-10-12
A 2026 preclinical study describes a CD300LD-targeted, biomimetic mRNA nanovaccine intended to activate tumor-associated neutrophils in mouse hepatocellular carcinoma. The reported antitumor and survival results support a proof of concept, but the evidence remains model-specific and does not establish human efficacy, clinical safety, or direct applicability to commercial neutrophil-isolation products.
-
BIRB 796 and p38α: Evidence Boundaries
2026-10-12
BIRB 796 (Doramapimod) is described by its supplier as an allosteric, selective p38α MAPK inhibitor. A 2024 bioRxiv preprint adds a broader mechanistic insight: some p38α inhibitors can both inhibit kinase activity and accelerate WIP1-mediated dephosphorylation, but the supplied abstract does not identify BIRB 796 among those compounds. The findings therefore support a conceptual framework for interpreting p38α signaling, not a compound-specific claim about cytokine control, apoptosis, or clinical efficacy.
-
Interpreting Multiplex Immunomodulator Screening Evidence
2026-10-11
A source-grounded assessment of a 2026 PBMC flow-cytometry screening study, emphasizing what its multiplex design supports, what its comparisons do not establish, and how the DiscoveryProbe™ Immunology/Inflammation Compound Library should be interpreted separately from the published assay evidence.
-
RG108 and Epigenetic Reprogramming: Evidence Overview
2026-10-10
RG108 is a small-molecule DNA methyltransferase inhibitor used as an epigenetic research probe. This overview examines its reported mechanism, the supplied mouse-brain reprogramming study, comparisons with valproic acid and other compounds, and the limits of interpreting marker-gene changes as evidence of pluripotency, tumor suppressor gene reactivation, or therapeutic activity.
-
(S,S)-Nanaomycin A: DNMT3B and NEPC
2026-10-09
(S,S)-Nanaomycin A is examined as a pharmacologic probe of DNMT3B-driven neuroendocrine plasticity in prostate cancer. This article separates the study’s findings from interpretation, evaluates evidence strength, and defines the limits of translating preclinical results toward therapeutic hypotheses.
-
DiscoveryProbe Bioactive Compound Library Plus: Evidence
2026-10-09
DiscoveryProbe Bioactive Compound Library Plus is a 5,072-compound research collection for broad pathway and target-focused screening. Its catalog scope supports hypothesis generation, while thermal-shift literature shows that apparent ligand effects require orthogonal binding confirmation.
-
Anlotinib and VEGFR2: Preclinical Angiogenesis Evidence
2026-10-08
The reference study characterizes anlotinib as a highly potent and selective VEGFR2 inhibitor and links biochemical activity with endothelial and tumor-angiogenesis phenotypes. Its integrated preclinical evidence supports further cancer research while also showing why results from cell, explant, and xenograft models should not be treated as clinical efficacy data.
-
PTEN mRNA Nanoparticles and Trastuzumab Resistance
2026-10-08
Dong et al. describe a tumor-microenvironment-responsive nanoparticle platform for systemic PTEN mRNA delivery in trastuzumab-resistant HER2-positive breast cancer models. The study links restored PTEN expression with suppression of PI3K/Akt signaling and shows how mRNA delivery could address a resistance mechanism that persists despite HER2-directed treatment, while remaining preclinical and model-dependent.
-
SGI-1027 and the Translational Logic of DNMT1
2026-10-07
SGI-1027 offers a useful framework for connecting DNMT1 perturbation with RB1 reactivation and gastric cancer phenotypes. This evidence-led analysis examines its mechanism, preclinical validation, translational boundaries, and strategic value for cancer epigenetics research.
-
nor-NOHA in Cancer and Vascular Research
2026-10-07
nor-NOHA is a reversible arginase inhibitor used as a research tool for studying arginine metabolism, nitric oxide biology, tumor phenotypes, and vascular function. Supplier-reported findings in HepG2 cells and a rat arthritis model suggest context-dependent effects, while a separate 2024 AML study establishes a CD36-dependent lipid and innate immune program without testing nor-NOHA. The evidence therefore supports hypothesis generation, not direct claims of efficacy or clinical translation.
-
Tc3 Pyroptosis and Combination Therapy in Hepatic Carcinoma
2026-10-07
The 2025 Theranostics study identifies the indole analogue Tc3 as a reported inducer of GSDME-mediated pyroptosis in hepatic carcinoma models. Its findings support a combination strategy with cisplatin or anti-PD-1 therapy, while also highlighting the need to distinguish pyroptosis from apoptosis when selecting cell-death readouts.